Anti-tuberculosis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Anti-tuberculosis Therapeutics Market is Segmented by Drug Class, End User (Hospitals and Clinics, Government Agencies, Non Profit Organizations, Other End Users), and Geography.

Market Snapshot

anti tuberculosis drugs market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Factors, such as rising prevalence of tuberculosis, growing initiative from government organization for tuberculosis awareness, collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are propelling the growth of the market studied.

According to the WHO’s 2020 Global Tuberculosis (TB) Report, a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent. Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB. This is, in turn, driving the growth of the global anti-tuberculosis therapeutics market, supported by the increasing global prevalence of TB and MDR-TB.

Scope of the Report

As per the scope of the report, Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies.

By Drug Class
Isoniazid
Rifampin
Ethambutol
Pyrazinamide
Fluoroquinolones
Bedaquiline
Amynoglycosides
Thioamides
Cyclic Peptides
Other Drug Classes
By End User
Hospitals and Clinics
Government Agencies
Non Profit Organizations
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hospitals/Clinics are Expected to Witness the Fastest Growth in the Coming Future

The WHO’s strategy to prevent TB includes engaging all relevant healthcare providers in tuberculosis (TB) care, while control through public-private mix approach remains an essential component of the strategy. The TB prevalence rate is more in countries, like China, India, and Africa, hence, the governments of these respective countries are trying to decrease the rate by increasing government initiatives and the number of hospitals.

As per 2019 Global Tuberculosis Report by the WHO, developing countries accounted for most of the global total TB cases, including India (27%), China (9%), Indonesia (8%), and the Philippines (6%). The developing countries mostly rely on the hospitals for healthcare access. Hence high incidence in the regions will boost the market in hospitals and clinics.

Graph.png

Asia-Pacific is Expected to be the Largest Market Over the Forecast Period

As per 2019 Global Tuberculosis Report by the WHO, geographically, most TB cases in 2018 were in the WHO regions of South-East Asia (44%), Africa (24%) and the Western Pacific (18%). As a result, a large number of cases are found in the Asia-Pacific region, which is expected to help the region dominate the market. Moreover, most of the global pharmaceutical companies have penetrated in developing countries like India and China, which is also expected to increase the availability of therapeutics and boost the market growth.

Geo.png

Competitive Landscape

The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in the R&D, imore small to mid-sized companies are estimated to enter into the market in the coming future.

Currently, companies such as Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd,  and Johnson and Johnson hold the largest market share.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Tuberculosis

      2. 4.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness

      3. 4.2.3 Rising Incidence of MDR and XDR Cases in Developing Countries

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Side Effects of Anti-tuberculosis Drugs

      2. 4.3.2 High Cost of MDR and XDR TB Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Isoniazid

      2. 5.1.2 Rifampin

      3. 5.1.3 Ethambutol

      4. 5.1.4 Pyrazinamide

      5. 5.1.5 Fluoroquinolones

      6. 5.1.6 Bedaquiline

      7. 5.1.7 Amynoglycosides

      8. 5.1.8 Thioamides

      9. 5.1.9 Cyclic Peptides

      10. 5.1.10 Other Drug Classes

    2. 5.2 By End User

      1. 5.2.1 Hospitals and Clinics

      2. 5.2.2 Government Agencies

      3. 5.2.3 Non Profit Organizations

      4. 5.2.4 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Lupin Limited

      2. 6.1.2 Macleods Pharmaceuticals Ltd

      3. 6.1.3 Otsuka Pharmaceutical Co. Ltd

      4. 6.1.4 Johnson and Johnson

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 Novartis AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Anti-tuberculosis Therapeutics Market market is studied from 2018 - 2026.

The Anti-tuberculosis Therapeutics Market is growing at a CAGR of 6.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Pfizer Inc., Lupin Limited are the major companies operating in Anti-tuberculosis Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!